London, March 2023: In the pharmaceutical field, SPCs, supplementary protection certificates, are extremely valuable intellectual property rights. An SPC extends the duration of the exclusive rights conferred by a patent and usually covers the period during which the medicinal product reaches peak sales and profitability. SPCs were introduced as compensation for the loss of effective patent term due to the lengthy time required to research and gain market approval for new medicinal products.
This report will cover some of the key questions and zoom in on national practices on the basis of specific examples. In addition, the report will cover the best approaches regarding the SPC Manufacturing Waiver, and also briefly cover the new Unitary Patent System. This report reflects the opinions from three industry experts: Jurgen Dressel, Patent Litigator and former Head of Patent Litigation Strategy at Novartis Pharma, Jaap Mannaerts, European Patent Attorney and Partner at NLO, and Judith Krens, Partner at Pinsent Masons.
It is beneficial to consider the context for these topics, and their complexities: the main goal of the EU legislation on SPCs and the SPC Manufacturing Waiver, was intended to stimulate and take away competitive disadvantages for pharmaceutical industries within the EU.
Download the full report here.
About Insight IP Ltd:
Insight IP are a global leading provider of services to Law Firms, Experts, and Counsel, specializing in legal document translations, disclosure, and document review, assistance to refine pleadings and witness statements, support to prepare expert reports, and assistance with pre-trial and hearing preparation. In addition, Insight IP manages a global network for IP executives that was established around an existing network of industry leaders. Members have access to exclusive knowledge sharing and networking benefits, as well as access to benchmarking and patent analysis studies.
Contact Information: Insight IP, Lucy James, Head of Operations, +44 (0) 207 846 0283, [email protected]